Loading...
XJPX
4571
Market cap42mUSD
Oct 09, Last price  
79.00JPY
1D
-2.47%
1Q
-25.47%
Jan 2017
-91.11%
IPO
-66.85%
Name

NanoCarrier Co Ltd

Chart & performance

D1W1MN
XJPX:4571 chart
P/E
—
P/S
37.66
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.39%
Rev. gr., 5y
-11.04%
Revenues
174m
+60.80%
103,000,000262,000,000353,000,000117,820,00084,337,000346,344,000373,778,000472,197,000675,801,000243,344,000218,694,000259,096,999496,732,000552,973,000313,264,000264,031,999202,189,000135,508,000108,516,000174,498,000
Net income
-944m
L+12.99%
-729,000,000-494,000,000-524,000,000-494,790,000-555,178,000-398,003,000-484,446,000-1,113,687,000-207,156,000-2,537,148,000-2,676,049,000-5,416,808,000-1,808,510,000-2,009,676,000-2,835,793,000-1,881,678,000-1,310,976,000-780,002,000-835,380,000-943,881,000
CFO
-817m
L+103.35%
-663,000,000-588,172,000-456,620,000-451,999,000-579,114,000-293,705,000-635,329,000-1,086,613,000-1,120,686,000-1,971,089,000-2,525,557,000-4,927,585,000-2,037,259,000-1,138,665,000-1,247,432,000-1,752,992,000-1,087,051,000-585,081,000-401,617,000-816,672,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.

Key people

Atsushi Matsumura
Chairman of the Board, President, Chief Executive Officer, Representative Director · since 2026
Shiro Akinaga
Chief Technology Officer, President of Subsidiary, Representative Director · since 2026
Satoru Iino
Chief Investment Officer, Director · since 2025
Norihiko Shiraishi
Executive Officer, Chief Scientific Officer, Manager of mRNA IPG Unit · since 2023
Koji Fujimoto
Chief Financial Officer, Executive Officer · since 2024
Yuuko Onodera
Executive Officer, Deputy Chief Director of Main Corporate Unit, Director of Accounting, Director of Research and Development Planning in Main Research and Development Unit · since 2023
Daisuke Takashima
Executive Officer, Chief Development Officer, Chief Director of Research Development · since 2023
Chieko Tsuchiya
Executive Officer, Director of Corporate Communication · since 2023
Ichiro Nakatomi
Chief Network Officer, Director · since 2025
Takashi Matsuo
Chief Administrative Officer, CCO, Director · since 2026
Nobuhiro Todokoro
Chief Growth Officer, Director · since 2025
Takashi Ejiri
Independent Director · since 2025
Hajime Kurozu
Independent Director · since 2024
URL
https://www.nanomrna.co.jp/
IPO date
Mar 05, 2008
Employees
17
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
港区愛宕２丁目５番１号
東京都, 13 105-6226
JP
Previous name
NanoCarrier Co., Ltd.
Other language
NANO Holdings Co., Ltd.

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT